Overview

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Status:
Recruiting
Trial end date:
2027-04-22
Target enrollment:
Participant gender:
Summary
The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Mirikizumab